U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06822855) titled 'Changing Paragidms in the Prognostic Assessment of Hodgkin Lymphoma' on Feb. 07.
Brief Summary: Classical Hodgkin's Lymphoma (cHL) is a rare but highly treatable malignancy of the immune system, primarily affecting young adults. Despite significant therapeutic advancements, frontline treatment failure occurs in up to 30% of cases, with relapse or refractory disease affecting over 50% of these patients. The main therapeutic challenge in cHL remains achieving an optimal balance between disease control and reducing long-term adverse effects. Current prognostic tools only partially capture patient heterogeneity, and cHL continues to evo...